Glenmark Q2 FY26 Earnings Results

Glenmark Pharmaceuticals Ltd, a global research-led company operating across generics, specialty, and OTC segments in over 80 countries, delivered a stellar performance in Q2FY26.

Financial Highlights:

• Revenues rose 76.09% year-on-year to ₹6,047 crore from ₹3,434 crore.
• Total expenses increased 29.8% to ₹3,894 crore from ₹3,000 crore.
• Consolidated net profit jumped 72.32% to ₹610 crore from ₹354 crore.
• Earnings per share climbed 72.35% to ₹21.63 from ₹12.55.

Key Insights:

• The profit surge was primarily driven by significant revenue growth from both generics and specialty business segments across global markets.
• Improved operating leverage and cost control helped maintain healthy margins despite the increase in expenses.
• The company’s diversified portfolio and strong international presence contributed to robust top-line and bottom-line expansion.

Outlook:

Glenmark aims to further strengthen its global footprint, accelerate launches in key markets, and expand its specialty and complex generics pipeline. Continuing investments in R&D and focus on operational efficiencies position the company for sustained medium-to-long-term growth.

Explore the company’s past earnings and latest concall transcripts, click here to visit the AlphaStreet India News Channel.